Homma Y, Kobayashi T, Yamaguchi H, Sakane H, Ozawa H, Matsuda M, Mikami Y, Mikami Y, Nakamura H
Department of Internal Medicine, Tokai University Oiso Hospital, Japan.
Artery. 1993;20(1):1-18.
The effects of 12 week probucol treatment on plasma lipoprotein subfraction levels and on lecithin: cholesterol acyltransferase (LCAT) and cholesteryl ester transfer protein (CETP) activities in type II hyperlipoproteinemia were investigated. Plasma VLDL-TG, VLDL-apoB, VLDL-apoCII and VLDL-apoCIII concentrations were not changed by probucol, but VLDL-TC and VLDL-PL levels were slightly reduced. Probucol slightly reduced plasma IDL-TC, but not IDL-TG, IDL-PL and IDL-apoB levels. Plasma large, light LDL (LDL1)-TC, LDL1-PL, LDL1-apoB levels were decreased significantly by 28.5 +/- 20.1% (p < 0.001), 18.1 +/- 18.8% (p < 0.01) and 23.3 +/- 19.1% (p < 0.001) by probucol treatment while LDL1-TG concentration was unchanged. Absolute amounts of plasma small, heavy LDL(LDL2)-TC, LDL2-TG, LDL2-PL and LDL2-apoB levels remained unchanged but percent increases of LDL2-TC and LDL2-apoB were statistically significant (p < 0.05). 2-16% gradient polyacrylamide gel electrophoresis demonstrated the diminution of LDL of large size by probucol treatment. Probucol markedly reduced plasma high density lipoprotein levels. The reductions of HDL2-TC, HDL2-TG, HDL2-PL and HDL2-apoAI concentrations were 36.2 +/- 25.4% (p < 0.001), 25.8 +/- 36.9% (p < 0.01), 34.4 +/- 23.8% (p < 0.001) and 35.6 +/- 28.4% (p < 0.001). Probucol significantly decreased plasma HDL3-TC, HDL3-PL and HDL3-apoAI amounts by 17.4 +/- 22.9% (p < 0.01), 18.3 +/- 20.8% (p < 0.01) and 19.8 +/- 27.9% (p < 0.01) without change of HDL3-TG level. The decrease of HDL2 level was more marked than that of HDL3 level. Probucol did not change LCAT activities. Probucol significantly stimulated CETP activities from 126.6 +/- 50.6 units to 172.8 +/- 40.2 units by 12 week treatment (p < 0.001). We concluded that probucol decreased plasma LDL1, HDL2 and HDL3 amounts and made them triglyceride-rich with the concomitant increase of CETP activities.
研究了普罗布考治疗12周对II型高脂蛋白血症患者血浆脂蛋白亚组分水平以及卵磷脂胆固醇酰基转移酶（LCAT）和胆固醇酯转运蛋白（CETP）活性的影响。普罗布考对血浆极低密度脂蛋白甘油三酯（VLDL-TG）、极低密度脂蛋白载脂蛋白B（VLDL-apoB）、极低密度脂蛋白载脂蛋白CII（VLDL-apoCII）和极低密度脂蛋白载脂蛋白CIII（VLDL-apoCIII）浓度无影响，但使极低密度脂蛋白胆固醇（VLDL-TC）和极低密度脂蛋白磷脂（VLDL-PL）水平略有降低。普罗布考使血浆中间密度脂蛋白胆固醇（IDL-TC）略有降低，但对IDL-TG、IDL-PL和IDL-apoB水平无影响。普罗布考治疗使血浆大的、轻的低密度脂蛋白（LDL1）-TC、LDL1-PL、LDL1-apoB水平分别显著降低28.5±20.1%（p<0.001）、18.1±18.8%（p<0.01）和23.3±19.1%（p<0.001），而LDL1-TG浓度未改变。血浆小的、重的低密度脂蛋白（LDL2）-TC、LDL2-TG、LDL2-PL和LDL2-apoB的绝对量未改变，但LDL2-TC和LDL2-apoB的百分比增加具有统计学意义（p<0.05）。2-16%梯度聚丙烯酰胺凝胶电泳显示普罗布考治疗使大尺寸低密度脂蛋白减少。普罗布考显著降低血浆高密度脂蛋白水平。高密度脂蛋白2胆固醇（HDL2-TC）、HDL2-TG、HDL2-PL和HDL2载脂蛋白AI（HDL2-apoAI）浓度分别降低36.2±25.4%（p<0.001）、25.8±36.9%（p<0.01）、34.4±23.8%（p<0.001）和35.6±28.4%（p<0.001）。普罗布考使血浆高密度脂蛋白3胆固醇（HDL3-TC）、HDL3-PL和HDL3-apoAI量分别显著降低17.4±22.9%（p<0.01）、18.3±20.8%（p<0.01）和19.8±27.9%（p<0.01），而HDL3-TG水平无变化。HDL2水平的降低比HDL3水平更明显。普罗布考不改变LCAT活性。普罗布考治疗12周使CETP活性从126.6±50.6单位显著升高至172.8±40.2单位（p<0.001）。我们得出结论，普罗布考降低血浆LDL1、HDL2和HDL3量，并使其富含甘油三酯，同时伴随CETP活性增加。
